Akebia Therapeutics, Inc.AKBANASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -17.26% | +75.84% | +43.13% | +57.01% | +23.92% |
| Gross Profit Growth | -30.37% | +66.30% | +48.66% | +110.88% | +73.75% |
| EBITDA Growth | -157.56% | +0.00% | +524.22% | +0.00% | +0.00% |
| Operating Income Growth | -1141.27% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -3814.01% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -3225.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -3225.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +15.16% | +14.90% | +25.21% | +25.88% | +21.34% |
| Weighted Average Shares Diluted Growth | +14.80% | +17.88% | +29.28% | +30.44% | +21.34% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -12.53% | +131.17% | +144.61% | +105.85% | +36.85% |
| Inventory Growth | +3.52% | -22.72% | -30.01% | -9.03% | -100.00% |
| Asset Growth | -8.70% | +37.57% | +56.95% | +75.80% | +70.65% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +292.20% | +26.36% | -49.00% | +3.47% | +14.61% |
| R&D Expense Growth | +19.47% | +0.24% | +44.02% | +72.33% | +126.10% |
| SG&A Expenses Growth | +8.80% | +0.00% | +0.00% | +13.10% | -5.73% |